for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Humanigen Inc

HGEN.O

Latest Trade

16.60USD

Change

0.35(+2.12%)

Volume

318,671

Today's Range

16.28

 - 

17.13

52 Week Range

7.50

 - 

33.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.25
Open
16.30
Volume
318,671
3M AVG Volume
27.26
Today's High
17.13
Today's Low
16.28
52 Week High
33.95
52 Week Low
7.50
Shares Out (MIL)
59.08
Market Cap (MIL)
959.52
Forward P/E
4.65
Dividend (Yield %)
--

Next Event

Q2 2021 Humanigen Inc Earnings Release

Latest Developments

More

Humanigen Submits Application To FDA For Emergency Use Authorization For Lenzilumab In COVID-19

Humanigen Reports Q1 Loss Per Share $1.25

Humanigen Reports Positive Data With Lenzilumab In The Zuma-19 CAR-T Phase 1B Study In DLBCL And Plans To Initiate Potential Registrational Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Humanigen Inc

Humanigen, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing immuno-oncology and immunology monoclonal antibodies. The Company’s Humaneered technology platform offers a method for converting existing antibodies into engineered human antibodies designed for therapeutic use, primarily for chronic conditions. It is focused on development of lead product candidate lenzilumab, a Humaneered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. Lenzilumab is a monoclonal antibody designed to target and neutralize human GM-CSF and prevents outcomes related to COVID-19. It is also developing lenzilumab as a treatment for autoimmune and other inflammatory conditions, including eosinophilic asthma, rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), atopic dermatitis (AD) and systemic lupus erythematosus (SLE).

Industry

Biotechnology & Drugs

Contact Info

533 Airport Blvd Ste 400

BURLINGAME, CA

94010-2013

United States

+1.650.2433100

https://www.humanigen.com/

Executive Leadership

Cameron Durrant

Chairman of the Board, Chief Executive Officer

Timothy Morris

Chief Financial Officer, Chief Operating Officer, Chief Accounting and Administrative Officer

Ken Trbovich

Senior Vice President of Investor Relations

Omar Ahmed

Senior Vice President - Clinical, Medical and Scientific Affairs

Dale Michael Chappell

Chief Scientific Officer, Director

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.4K
EPS (USD)

2020

-2.420

2021(E)

3.148
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,202.41
Price To Book (MRQ)
51.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
143.59
LT Debt To Equity (MRQ)
143.59
Return on Investment (TTM)
-997.88
Return on Equity (TTM)
-307.48

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up